320 completed, 37 unknown, 33 recruiting, 25 not yet recruiting. 263 Phase 1, 73 Phase 2, 53 Phase 3, 42 Phase 4, 30 Not applicable.
Follow Rifampin: new trials by email Literature Review of Rifampin trials Research Report on Rifampin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 HRS-8080, Rifampicin - Breast Cancer | Phase 1 | Not yet recruiting | Shandong Suncadia Medicine Co., Ltd. | 18 | 2026-11-01 | 2026-10-15 |
| All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin) - Brucellosis, Osteoarticular Brucellosis | Not applicable | Not yet recruiting | The First Affiliated Hospital of Shihezi University | 150 | 2026-11-01 | 2026-10-21 |
| Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin - Brucellosis | Not applicable | Not yet recruiting | The First Affiliated Hospital of Shihezi University | 200 | 2026-11-01 | 2026-10-21 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11 TBD11 (300 mg), Placebo, Itraconazole (200 mg) - Healthy Adult Participants | Phase 1 | Recruiting | Gates Medical Research Institute | 66 | 2026-10-21 | 2026-10-22 |
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2026-10-01 | 2026-09-29 |
| Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | TASK Applied Science | 135 | 2026-09-25 | 2026-09-25 |
| A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults Itraconazole, Rifampicin, Omeprazole - Healthy Subjects | Phase 1 | Not yet recruiting | InventisBio Co., Ltd | 60 | 2026-09-16 | 2026-10-15 |
| Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE) Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin - Brucellosis, Osteoarthritis | Not applicable | Not yet recruiting | The First Affiliated Hospital of Shihezi University | 350 | 2026-09-01 | 2026-08-21 |
| Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants vorolanib and rifampicin, vorolanib and itraconazole - DDI (Drug-Drug Interaction) | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 36 | 2026-09-01 | 2026-09-09 |
| A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) MK-8527, Rifampin - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 14 | 2026-09-01 | 2026-08-03 |
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants. Befotertinib and rifampicin, Befotertinib and itraconazole - DDI (Drug-Drug Interaction) | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 36 | 2026-09-01 | 2026-09-09 |
| A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants Navlimetostat, Itraconazole, Rifampin - Healthy Female Adults | Phase 1 | Recruiting | Bristol-Myers Squibb | 80 | 2026-08-31 | 2026-10-05 |
| A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504 HS-10504, Rifampin - Healthy Participants | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 18 | 2026-08-02 | 2026-08-18 |
| Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet RSS0343 Tablet; Rifampicin Capsules, RSS0343 Tablet; Clarithromycin Tablets - Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease | Phase 1 | Not yet recruiting | Reistone Biopharma Company Limited | 40 | 2026-07-01 | 2026-07-10 |
| Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction QLC5508 (Investigational Product / Formulation T), QLC5508 (Reference Product / Formulation R), Itraconazole - Refractory or Relapsed Solid Tumors | Phase 1 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 48 | 2026-06-09 | 2026-09-15 |
| Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants MDR-001, Rifampin, Itraconazole - Healthy Volunteers (HV) | Phase 1 | Not yet recruiting | MindRank AI Ltd | 28 | 2026-05-06 | 2026-04-24 |
| Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women Standard dose rifampicin, High dose rifampicin, Standard dose isoniazid - Tuberculosis Infection, Healthy Volunteer | Phase 1 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 60 | 2026-04-01 | 2026-02-10 |
| Drug Interaction and Food Effect Study of CS0159 CS0159 Tablet, Rifampicin Capsule, Itraconazole Capsule - Healthy Volunteers | Phase 1 | Completed | Cascade Pharmaceuticals, Inc | 32 | 2026-03-09 | 2026-06-03 |
Showing 20 of 455. Sign in to see all of them.
Tuberculosis (83) · Tuberculosis, Pulmonary (53) · HIV Infections (22) · Latent Tuberculosis (14) · Acquired Immunodeficiency Syndrome (13) · Neoplasms (13) · Lymphoma (8) · Lymphoma, Non-Hodgkin (7) · Tuberculosis, Meningeal (7) · Cystic Fibrosis (6) · Infections (6) · AIDS-Related Opportunistic Infections (5) · Mycobacterium Infections (5) · Staphylococcal Infections (5) · Tuberculosis, Multidrug-Resistant (5)
National Institute of Allergy and Infectious Diseases (NIAID) (20) · Boehringer Ingelheim (11) · Pfizer (11) · Bristol-Myers Squibb (10) · AstraZeneca (9) · Johns Hopkins University (9) · Celgene (8) · Jiangsu HengRui Medicine Co., Ltd. (8) · Centers for Disease Control and Prevention (7) · Millennium Pharmaceuticals, Inc. (7) · University of California, San Francisco (7) · Global Alliance for TB Drug Development (6) · Janssen Research & Development, LLC (6) · Bayer (5) · GlaxoSmithKline (5)
United States (153) · China (71) · South Africa (48) · Uganda (26) · Canada (24) · United Kingdom (19) · Brazil (15) · Germany (15) · India (15) · South Korea (14) · France (13) · Tanzania (13) · Philippines (12) · Spain (12) · Netherlands (11)
Nicholas Paton (6) · Susan Dorman, MD (5) · Janne Hukkanen, MD, PhD (4) · Dick Menzies, MD (3)
PMID 35229613, PMID 36808186, PMID 41744113, PMID 31866327, PMID 32539440, PMID 32785709, PMID 33542052, PMID 36511181, PMID 36949623, PMID 38768617, PMID 10798549, PMID 11448564, PMID 12809582, PMID 14557966, PMID 14986270, PMID 15276398, PMID 15329363, PMID 15840453, PMID 16141439, PMID 16470119, PMID 16574936, PMID 16675781, PMID 16982292, PMID 16988514, PMID 17192170, PMID 17504682, PMID 17576825, PMID 17928422, PMID 18366444, PMID 18795962, PMID 18818959, PMID 18989231, PMID 19146007, PMID 19542476, PMID 19588358, PMID 19965813, PMID 20002783, PMID 20155838, PMID 20176900, PMID 20627913, PMID 20632458, PMID 20675299, PMID 20979469, PMID 20979472, PMID 21283017, PMID 21410904, PMID 21422405, PMID 21453653, PMID 21623265, PMID 21732833
2016 (6), 2018 (6), 2019 (5), 2017 (3), U01AI068636 (3), 2014 (2), 2009 (1), 2015 (1), 2025 (1), K23HD068497 (1), P01GM032165 (1), P01NS044233 (1), P30CA014520 (1), R01AI048526 (1), R01DK112955 (1)